La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Starpharma Holdings Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Starpharma Holdings.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	28.4%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

May 16

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20

Recent updates

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Nov 22

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Mar 21

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Mar 02

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Feb 10

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

Dec 28

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Dec 07

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Starpharma Holdings non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

ASX:SPL - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2023	11	-8	-7	-6	N/A
9/30/2023	7	-12	-10	-10	N/A
6/30/2023	4	-16	-14	-14	N/A
3/31/2023	5	-16	-11	-10	N/A
12/31/2022	5	-16	-8	-7	N/A
9/30/2022	5	-16	-11	-10	N/A
6/30/2022	5	-16	-14	-13	N/A
3/31/2022	5	-17	-18	-17	N/A
12/31/2021	4	-18	-21	-21	N/A
9/30/2021	4	-19	-18	-18	N/A
6/30/2021	3	-20	-15	-15	N/A
3/31/2021	3	-19	-13	-13	N/A
12/31/2020	3	-19	-11	-11	N/A
9/30/2020	5	-17	-11	-11	N/A
6/30/2020	7	-15	-11	-11	N/A
3/31/2020	7	-14	-10	-10	N/A
12/31/2019	8	-13	-8	-8	N/A
9/30/2019	5	-14	-10	-9	N/A
6/30/2019	3	-14	-11	-10	N/A
3/31/2019	4	-13	-9	-8	N/A
12/31/2018	4	-11	-7	-6	N/A
9/30/2018	5	-11	-9	-8	N/A
6/30/2018	5	-10	-11	-10	N/A
3/31/2018	5	-12	N/A	N/A	N/A
12/31/2017	4	-13	-19	-18	N/A
9/30/2017	4	-14	N/A	-18	N/A
6/30/2017	4	-15	N/A	-17	N/A
12/31/2016	1	-20	N/A	-20	N/A
9/30/2016	3	-20	N/A	-19	N/A
6/30/2016	5	-21	N/A	-18	N/A
3/31/2016	5	-22	N/A	-17	N/A
12/31/2015	5	-20	N/A	-16	N/A
9/30/2015	3	-20	N/A	-15	N/A
6/30/2015	2	-19	N/A	-14	N/A
3/31/2015	1	-18	N/A	-11	N/A
12/31/2014	1	-18	N/A	-9	N/A
9/30/2014	1	-16	N/A	-9	N/A
6/30/2014	1	-15	N/A	-10	N/A
3/31/2014	2	-12	N/A	-8	N/A
12/31/2013	2	-9	N/A	-6	N/A
9/30/2013	2	-7	N/A	-8	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista SPL è superiore al tasso di risparmio ( 2.4% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di SPL cresceranno più velocemente del mercato Australian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di SPL cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di SPL cresceranno più rapidamente del mercato Australian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di SPL cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di SPL è previsto essere elevato tra 3 anni

Starpharma Holdings Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Forecast to breakeven in 2022

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Price target raised to AU$2.03

Analysts lower revenue estimates to AU$9.89m

Price target raised to AU$1.73

Recent updates

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary

Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia

Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca

Starpharma Holdings Limited Announces Management Changes

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022

Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO

Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model

Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray

Starpharma Holdings Limited Appoints Jeff Davies as Director

Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron

Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel

Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Starpharma Releases New Data About SPL7013

Forecast to breakeven in 2022

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Starpharma Signs DEP ADC Research Agreement with MSD

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion

New 90-day high: AU$1.80

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Price target raised to AU$2.03

New 90-day high: AU$1.68

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Announces SPL7013 Shows Potent Antiviral Activity in RSV Expanding Use for Nasal Spray

Starpharma Holdings Limited announced that it has received AUD 45 million in funding

Starpharma Holdings Limited announced that it expects to receive AUD 45 million in funding

Starpharma Holdings Limited Announces That Australia Therapeutic Goods Administration Approves Expansion of the Marketing Authorisation for Vivagel® Bv

New 90-day high - AU$1.73

Analysts lower revenue estimates to AU$9.89m

Price target raised to AU$1.73

Earnings released

New 90-day high - AU$1.30

New 90-day high - AU$1.19

Previsioni di crescita degli utili e dei ricavi